SignalFDA/Bio
Moderna (MRNA) Gets Phase 3 Melanoma Vaccine Validation At ESMO And NEJM
Moderna's Phase 3 melanoma vaccine validation at ESMO and NEJM signals major clinical catalyst.
Context
What happened: Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data at ESMO 2026 for their individualized mRNA melanoma vaccine, intismeran, combined with KEYTRUDA.
Why it matters: The data support expectations for oncology revenue and the individualized manufacturing process as a moat, and analysts point to regulatory filings, adjuvant melanoma approvals, and reimbursement as the next tests of real world uptake.
Market: -3.2% today ($140.61), +33.1% YTD, 1.3x vol — as of 23:45 UTC
Verified: Q3_2026 (Oct 29) revenue $17.3B vs $17.3B est; next print ~Jan 28
What changed
Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data at ESMO 2026 for their individualized mRNA melanoma vaccine, intismeran, combined with KEYTRUDA.
Why it matters
The data support expectations for oncology revenue and the individualized manufacturing process as a moat, and analysts point to regulatory filings, adjuvant melanoma approvals, and reimbursement as the next tests of real world uptake.
Market: -3.2% today ($140.61), +33.1% YTD, 1.3x vol — as of 23:45 UTC
Verified: Q3_2026 (Oct 29) revenue $17.3B vs $17.3B est; next print ~Jan 28